The chorda tympani branch of the facial nerve is the anatomical key to understanding taste loss with facial palsy — taste from the anterior two-thirds of the tongue is carried by the chorda tympani (a branch of the facial nerve CN VII), which travels through the middle ear before joining the lingual nerve. In Bell's palsy (idiopathic facial nerve inflammation), the entire facial nerve is affected, including the chorda tympani branch, causing: ipsilateral taste loss from the anterior tongue + ipsilateral loss of lacrimation (greater petrosal nerve) + hyperacusis (nerve to stapedius). The patient may not volunteer taste loss unless specifically asked — 'Have you noticed any change in how food tastes?' should be a routine question in any facial palsy assessment. Ramsay Hunt syndrome (herpes zoster oticus) involves the geniculate ganglion of the facial nerve and typically causes: severe otalgia (ear pain, often the first symptom) + ipsilateral facial palsy + vesicles in the external ear canal/auricle (sometimes on the soft palate) + sensorineural hearing loss + vertigo. It has a worse prognosis than Bell's palsy, and incomplete recovery is more common. Treatment is time-sensitive: it requires same-day specialist assessment; start antiviral treatment promptly, ideally within 72 hours, and discuss corticosteroid treatment with the specialist/local pathway.

Understanding the physiology of flavour is essential for accurate diagnosis and patient education — if a GP tells a patient who has post-COVID anosmia that they have 'lost their sense of taste,' the patient will search for ageusia treatments, not anosmia treatments. The correct explanation is: 'You have lost your sense of smell, and because most of what we experience as taste is actually smell, your food has no flavour. But your actual taste receptors — for sweet, salt, sour, bitter — are working normally.' This explanation is accurate, helps the patient understand why antihistamines won't help, and correctly directs them toward olfactory training. The gustin (carbonic anhydrase VI) — zinc connection is mechanistically important: gustin is secreted by serous acinar cells of the parotid gland into saliva, where it acts as a trophic factor for taste receptor cell maturation and maintenance. In zinc deficiency, gustin activity falls, taste bud maintenance is impaired, and hypogeusia and dysgeusia result. Even so, do not empirically prescribe high-dose zinc for idiopathic or post-viral dysgeusia (see Step 7).

Drug-induced dysgeusia is far more common than most clinicians appreciate and is the most commonly missed cause in primary care — for many patients the taste change is the most bothersome side effect of their medication. The mechanism varies by drug: (1) drugs excreted in saliva affect taste directly at the receptor level (metronidazole, metformin — both achieve high salivary concentrations, producing a persistent metallic taste); (2) drugs that chelate zinc impair taste receptor function (captopril — its sulfhydryl group chelates zinc — and penicillamine; zinc is essential for carbonic anhydrase VI in taste buds); (3) drugs that reduce salivary flow (anticholinergics, antihistamines, antidepressants) cause dry mouth → altered taste by reducing the aqueous medium for taste molecule delivery to receptors. Terbinafine deserves special mention: it is lipophilic, accumulates in keratin-rich tissues including taste receptor cells and is released slowly, so a bitter or metallic dysgeusia can be severe enough to cause weight loss and depression and may persist for months after stopping (case reports up to 12 months). Patients who completed a course for onychomycosis may not connect the drug — ask specifically about terbinafine use in the past 12 months, and warn patients starting terbinafine about this effect. Clarithromycin commonly causes a bitter metallic taste — patient education prevents early discontinuation of important antibiotic courses.

Serum zinc testing for taste disorders should be targeted — zinc deficiency is a potentially reversible cause of hypogeusia and dysgeusia, and testing is worth considering in at-risk groups: elderly patients (reduced dietary intake + reduced absorption), patients taking zinc-chelating drugs (penicillamine, captopril, tetracycline), vegetarians and vegans (plant phytates inhibit zinc absorption), malnutrition, malabsorption (coeliac disease, inflammatory bowel disease, short bowel syndrome, bariatric surgery), chronic diarrhoea, restrictive diet, alcohol dependence, long-term PPI therapy, and unexplained alopecia, dermatitis or poor wound healing. Serum zinc behaves as a negative acute-phase reactant — it falls during inflammation/infection and may be low-normal while tissue zinc is deficient — so interpret it against the local laboratory range, with albumin and inflammatory status. In primary care, history and simple patient-reported testing usually separate true taste loss from olfactory-driven flavour loss; the majority of patients reporting taste loss after COVID-19 who undergo formal gustometry have normal true taste function, confirming anosmia as the actual problem.

Parosmia is one of the most distressing sequelae of COVID-19 olfactory damage — it is a distorted smell perception where familiar odours are perceived as disgusting (coffee smelling like petrol, meat smelling like rotting, or sweet foods smelling like chemicals). Parosmia can occur with persistent post-COVID smell dysfunction and is characterised by: onset several weeks after the acute infection (rather than at the same time); worsening with strong smells; specific trigger foods or household smells; and profound impact on quality of life, appetite, and mental health. Paradoxically, parosmia is a positive prognostic sign — it indicates that olfactory nerve fibres are regenerating (misrouted regenerating axons interpret incoming signals incorrectly, creating the distorted perception). Most patients with parosmia eventually recover, though the timeline is months to years. The management: continue olfactory training (evidence suggests it accelerates parosmia resolution), avoid major trigger foods temporarily (adapt diet around the parosmia without eliminating all food groups — dietitian referral if significant weight loss), and address the psychological impact (anxiety and depression are extremely common — PHQ-9 and GAD-7, NHS Talking Therapies referral).

Bell's palsy with taste involvement helps localise the lesion — the chorda tympani branch of CN VII leaves the facial nerve within the facial canal. If taste is preserved, the lesion is distal to the chorda tympani exit; if taste is impaired, the lesion is more proximal (geniculate ganglion or above). This does not change initial management but provides prognostic information — more proximal lesions with taste involvement tend to have slower and less complete recovery, so document the presence or absence of taste in all Bell's palsy presentations. Dietitian referral for cancer-related dysgeusia (common in chemotherapy patients) is an underused intervention — specific strategies include plastic cutlery, serving food cool or at room temperature, marinating meat in fruit juices, using tart flavours (lemon, vinegar), and non-meat protein sources (dairy, eggs, legumes) when meat tastes unpleasant.

The most useful intervention in taste loss is a systematic medication review: list every drug (including OTC and herbal) the patient takes, check each for taste-related adverse reactions in the BNF/electronic medicines compendium, and review the temporal relationship and alternatives with the prescriber. The bicarbonate of soda mouthwash strategy for metallic dysgeusia comes from oncology practice — metallic taste in chemotherapy patients is partly caused by acidic by-products of taste receptor cell damage, and rinsing with an alkaline bicarbonate solution before meals partially neutralises this, improving perceived food taste. The same advice can be applied to drug-induced metallic dysgeusia from any cause.

The olfactory training protocol (smell training) for post-viral anosmia is a reasonable, low-risk intervention for post-infectious smell loss (it is not a proven treatment for all taste disorders) — a systematic review and meta-analysis (Pekala et al., Int Forum Allergy Rhinol 2016; 10 studies, 639 patients) found that olfactory training improved smell function compared with controls. The mechanism is neuroplasticity — repeated activation of olfactory neural pathways stimulates axonal regeneration and cortical reorganisation of olfactory processing areas. The original Hummel protocol (2009) used 4 scents representing the 4 odour categories in the Henning odour prism (flowery, fruity, resinous, aromatic/spicy), sniffed for 20 seconds per odour, twice daily. Subsequent research (Altundag 2015) showed that 'modified' smell training — changing the 4 scents every 12 weeks — was more effective than using the same 4 scents continuously. Patient motivation and adherence are the main determinants of response. Pilocarpine is a muscarinic (M3) agonist that stimulates remaining functional salivary acinar cells; side effects (sweating, flushing, increased lacrimation, urinary frequency) are dose-dependent. Initiation in Sjögren's is typically specialist-led (rheumatology), and GPs can continue and adjust the prescription; for post-radiotherapy xerostomia it produces a modest improvement in salivary flow and patient-reported taste and quality of life.

Anticholinergic burden and xerostomia is a critically important interaction in elderly patients — anticholinergic drugs (tricyclic antidepressants, oxybutynin, tolterodine, solifenacin, diphenhydramine, chlorphenamine, procyclidine, hyoscine, first-generation antihistamines, antipsychotics, antiemetics) suppress parasympathetic stimulation of salivary glands, causing dry mouth and the associated taste impairment, caries and worsening dysphagia. In elderly patients with polypharmacy, the cumulative anticholinergic burden can be substantial — the Anticholinergic Cognitive Burden (ACB) score quantifies this. High ACB scores are associated not only with dry mouth and constipation, but also with cognitive impairment, falls, and urinary retention. GPs who identify taste disorder + dry mouth in an elderly patient should specifically calculate the anticholinergic burden and consider whether any anticholinergic drugs can be stopped or substituted. The STOPP criteria specifically identify antidepressants with anticholinergic properties, bladder antimuscarinic drugs for overactive bladder, and first-generation antihistamines as potentially inappropriate in older adults. Burning mouth syndrome affects primarily peri- and post-menopausal women: chronic burning of the tongue, lips or palate without visible lesions, often with altered (metallic, bitter) taste and a dry-mouth sensation, typically absent on waking and worst in the evening. It is idiopathic in most cases but can be secondary to nutritional deficiency (iron, B12, zinc, folate), dry mouth, oral candidiasis, contact hypersensitivity (dental materials) or psychosocial factors.

The umami receptor strategy is scientifically grounded — the umami receptor (T1R1/T1R3 heterodimer, sensitive to glutamate and nucleotides) is often partially preserved in conditions causing dysgeusia. Umami-rich foods (parmesan, soy sauce, miso, anchovies, sun-dried tomatoes, dried shiitake mushrooms) make food more palatable even when sweet/salty/bitter perception is diminished; this comes from culinary medicine and oncology nutrition, where umami enhancement is standard advice for chemotherapy-related dysgeusia. The AbScent charity was founded by a chemosensory scientist who herself experienced post-viral anosmia and provides smell-training guides, a peer-support community (particularly valuable for parosmia) and clinician information; Fifth Sense provides similar UK support. GPs should routinely signpost post-viral taste/smell patients to these resources — combined with GP support (olfactory training, mental health assessment) this improves wellbeing and adherence.

Most Bell's palsy patients achieve complete or near-complete recovery with corticosteroid treatment within months. However, a minority have incomplete recovery, and some develop synkinesis (involuntary facial movements linked to intentional movements, caused by aberrant nerve regeneration — e.g. the eye closes when smiling), hemifacial spasm, or crocodile tears (lacrimation when eating). Persistent weakness or synkinesis is best managed through a facial-palsy/ENT/neurology pathway rather than a routine EMG at a fixed time point — specialist assessment may include EMG, facial rehabilitation physiotherapy, botulinum toxin for synkinesis and, in selected cases, surgery. The GP should ensure these patients have follow-up arranged rather than being discharged with incomplete recovery. For persistent unexplained taste loss despite correction of reversible factors, specialist smell and taste services can provide electrogustometry, formal threshold testing and access to research, even if access is geographically limited.